The Bial 10-2474 Phase 1 Study—A Drug Development Perspective and Recommendations for Future First-in-Human Trials
This month’s editor’s choice article reviews using previously unavailable data, the incident with the drug Bial-10-2474 and the resultant death of a healthy volunteer in 2016. The study conducted by Biotrials was a multiple ascending dose study in healthy volunteers. The author of this manuscript, an individual who has been involved with drug development for decades, reviews and analyzes the issues involved with this study and offers expert recommendations. The paper is not meant to be a complete review of the topic, but meant to open a discussion about phase I study conduct.
-- Philip Chaikin,
- Article Category
- Editor's Choice: Review
The Bial 10‐2474 Phase 1 Study—A Drug Development Perspective and Recommendations for Future First‐in‐Human Trials
- First Published:
- | Vol:
- | DOI:
Log in for Access
Log in for access to all ACCP journal content if you are an ACCP member.
to ACCP1.org for access) (Note: you will be redirected
Download the JCP App
iOS App for iPad or iPhone